• Home
  • » 
  • Reports
  • » 
  • Digital Manufacturing Market for Biologi...

Digital Manufacturing Market

Digital Manufacturing Market for Biologics - Distribution by Type of Technology, Deployment Options, Types of Biologics Manufactured, and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 4,799

  • Published
    March 2023

  • Pages
    254

  • View Count
    7049

  • Buy Now

Example Insights

The image provides context of digital manufacturing market for biologics. Upon realizing the potential of digital biomanufacturing over traditional processes, players are actively undertaking initiatives to adopt advanced platforms to drive operational excellence, visibility, control and synchronization in bioprocessing Digital-Biomanufacturing-Market-Service-Providers-thumb The snapshot higlights digital manufacturing market overview. 140+ platforms, based on PAT, DAS, MES, digital twins and other such technologies, are being offered for digitalization of the biologic production process The image provides digital biomanufacturing market distribution. Over 85% of the process analytical technologies are capable of offering process automation and bioprocess optimization and controls; majority of these platforms support manufacturing of proteins and antibodies
The image provides digital manufacturing software analysis. Data analysis software offer a wide spectrum of technical competencies, including process intelligence and data integration; predominantly, these platforms are compatible with artificial intelligence-based programs This image highlights integration of digital manufacturing with manufacturing execution systems. Leveraging their expertise, ~80% players are offering cloud-based MES solutions that can be integrated with numerous types of software to carry out production tracking, performance analysis and data integration functions This image highlights integration of digital manufacturing with digital twin. The developer landscape is dominated by the presence of established players; asset / process management emerged as the prominent application areas for digital twin technologies The image highlights digital manufacturing company competitiveness analysis. In pursuit of gaining a competitive edge, digital biomanufacturing providers are upgrading their existing software capabilities and enhancing their biologic focused technology portfolios
The image highlights the level of partnership activity in digita manufacturing market. The growing preference for digitalization of bioprocessing is evident from the rise in partnership activity; it is worth highlighting that more than 80% of the deals were forged in the last three years This infographic provides details on where the digital manufacturing market is concentrated. Being a relatively concentrated market, players are focused on developing unique selling propositions for their technology platforms and become strategic partners for biologic developers The image provides a benchmark analysis for digital biomanufacturing companies. The adoption of digital biomanufacturing solutions has increased considerably in recent years; white spaces in this domain present significant growth opportunities for innovators The image highlights digital biomanufacturing industry lifecycle analysis. Fundamental advancements in the field of smart biomanufacturing will promote process robustness and product quality; this will inevitably culminate in accelerated growth of the market
The image provides an estimated of digital manufacturing market size. Driven by the continuous technological innovations, this domain is anticipated to witness steady growth; technologies focused on digital twins are expected to gain significant traction with an annualized growth of 19% This image provides digital manufacturing market segmentations. The projected opportunity for digital bioprocessing platforms is expected to be well distributed across different types of biologics and key geographical regions    

 

Report Description

Digital Transformation In Biologic Manufacturing Overview

The global digital manufacturing market for biologics is anticipated to grow at a compounded annual growth rate (CAGR) of 18% during the forecast period, driven mainly by the increased focus on industry 4.0 technologies. Digital transformation has also garnered the interest of pharmaceutical industry. It involves incorporating digital technologies across all functions / operations. Digital technologies have been impacting drug discovery to clinical development as well as manufacturing, amongst other functions. Since the outbreak of COVID-19 infection, there has been immense pressure on the biopharmaceutical industry to reduce production timelines and increase the manufacturing capacity, without compromising on the quality of the final product. Further, a surge in morbidity across the globe and enhanced interconnectivity of equipment and technologies has led to an increased burden on manufacturing operations. Other factors that influenced the market include higher competition, competitive pricing, inflation rate, technological advancements and evolving regulatory guidelines. These factors demanded a fundamental shift from conventional manufacturing operations, which subsequently led to the introduction of industry 4.0 technologies. Digital transformation in pharma / biopharma manufacturing has emerged as a promising alternative to mitigate a number of bioprocessing related concerns, as well as significantly promote process robustness and product quality.

Digital manufacturing of biologics, popularly known as digital biomanufacturing or bioprocessing 4.0, refers to the integration of physical equipment with digital software and platforms, such as process analytical technology(PAT), data analysis software (DAS), manufacturing execution systems (MES) and digital twin, in order to streamline the overall biomanufacturing process. Implementation of these technologies in monitoring, analytics and computing capabilities is expected to revolutionize current biomanufacturing practices. Further, digital bioprocessing is believed to have transformed manufacturing principles in areas, such as process development, operational activities, logistics and supply chain management, when used in combination with advanced technologies, including artificial intelligence (AI), machine learning and internet of things (IoT).

Key Market Insights

The Digital Manufacturing Market for Biologics: Distribution by Type of Technology (Process Analytical Technology, Data Analysis Software, Manufacturing Execution System and Digital Twin), Deployment Options (Cloud-based and On-premises), Type(s) of Biologic(s) Manufactured (Antibodies, Cell Therapies and Gene Therapies, Proteins, Vaccines, and Others), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and the likely future potential of the digital biomanufacturing market, over the forecast period. It highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key inclusions of the research report are briefly discussed below:

Growing Demand for Biologics

Breakthroughs in the biotechnology industry, over the last few decades, has provided a considerable boost to the overall development landscape of biopharmaceutical drugs. In 2022, a milestone was witnessed when the number of approvals received by biologics narrowly outpaced those reported by small molecules. Further, in the same year, nearly half of the biologic approvals were allotted to novel class of modalities, including antibody drug conjugates (ADCs), bispecific antibodies, cell therapies and gene therapies. This can be attributed to the fact that the demand for biologics has been constantly increasing and is supported by continuous innovation in this field. Specifically, advancements in niche segments is expected to culminate in accelerated growth of the biologics market. 

Need for Digital Manufacturing of Biologics 

According to a recent report, the development of a new drug takes 10-15 years, with an overall investment of USD 1-2 billion. Despite the significant investment of resources, over 90% of the candidates fail at different stages of clinical trials, resulting in huge financial losses for biomanufacturers.  

As a direct consequence of the consistently growing demand for biologics and the existing challenges, there is an increase in the requirement for solutions that help in establishment of a digitally enabled and connected end-to-end process, in order to optimize bioprocess operations. Research suggests that, at present, 20% of the organizations have already adopted digitalized approaches for biomanufacturing. Such approaches are expected to enable an uninterrupted and accessible supply of cost-effective drugs that are likely to be launched commercially, with reduced development timelines. In fact, several leading biopharma players have claimed to achieve 40% increase in quality, 15% reduction in cost, 80% decrease in process variability and 20% shorter operational timelines by leveraging digital biomanufacturing advances. All these factors will drive the digital biomanufacturing market growth during the forecast period.

Key Advantages of Digital Biomanufacturing

Currently, batch-to-batch variation and product validation are considered as major bottlenecks faced by the biologic industry. Digital biomanufacturing harnesses various advancements, such as real-time monitoring, data analytics, automation, modelling, process optimization and other digital tools to transform the available information into actionable insights. This is expected to help in the creation of a uniform process, which is capable of decreasing the deviation in quality of each batch. Other key benefits of digital biomanufacturing include improved efficiency, higher product yield, better product quality, data integrity, reduced manual intervention and limited risk of contamination. It is worth noting that digitalization in biopharmaceutical manufacturing is becoming an essential requirement, given its potential to develop enhanced quality products, with high speed, agility and sustainability. The benefits offered by digital tools in manufacturing will drive the market growth over the forecast period.

Digital Biomanufacturing Market Landscape: Digital Twin Companies Have Launched Process Digital Twin to Support Biologic Manufacturing

The digital biomanufacturing providers landscape features a mix of large, mid-sized and small companies, which have the required expertise and offer various digital services for the production of biologics. At present, more than 140 digital technologies have been / are being developed by over 100 industry stakeholders to enable the manufacturing of biologics. Further, various types of technologies currently facilitate smart biomanufacturing; of these, 48% are based on the principles of Process Analytical Technology, followed by those using Manufacturing Execution System (28%), Data Analysis Software (14%) and digital twin (10%). 

Another digital tool supporting digital transformation of biologic manufacturing are the data analysis software. They offer wide spectrum of technical competencies, including process intelligence and data integration. We have identified more than 15 data analysis software companies established across the globe, offering 20+ data analysis software solution developed for biologic manufacturing applications.

Digital Manufacturing Market Size: Process Analytical Technology Market Segment Holds the Largest Market Share

The global digital manufacturing market for biologics is anticipated to be worth around USD 15 billion. Driven by improved data analytics, better product yield, faster production timelines, access to real time operations and rising interest in paperless manufacturing amongst innovators, lucrative opportunities are expected to emerge for players offering bioprocessing 4.0 services. The digital biomanufacturing market is anticipated to grow at a CAGR of 18%, during the forecast period 2023-2035. 

In terms of type of technology, the process analytical technology market holds 35% share of the digital biomanufacturing market. Over 85% of the process analytical technology platforms are capable of offering process automation and bioprocess optimization and controls. Majority of the PAT platforms support the manufacturing of proteins and antibodies. However, in terms of market growth, the digital twin market is expected to grow at a relatively high CAGR of 27%, during the forecast period. 

Key Trends in the Digital Manufacturing of Biologics: A Number of Manufacturing Execution System are Offering Cloud-Based Deployment Options

Many stakeholders are undertaking initiatives to forge alliance with other industry / non-industry players. It is worth highlighting that over 75 strategic partnerships related to digital biomanufacturing have been inked since 2018, indicating that software providers are actively upgrading their technology related capabilities and accommodating the current and anticipated demand for digital biomanufacturing. Given the inclination towards cutting-edge technologies, along with innovative approaches to tailor the bioprocessing, we believe that the digital biomanufacturing technologies market is likely to evolve at a rapid pace, over the forecast period. ,  

Further, currently, the market for on-premise deployment options is expected to capture the majority market share; however, this trend is likely to change in the foreseen future with the rising popularity of cloud-based technologies. Nearly 80% of the manufacturing execution system companies are offering cloud-based MES solutions that can be integrated with numerous types of software to carry out production tracking, performance analysis and data integration functions. The availability of such cloud-based manufacturing execution system will drive the market size of MES market over the forecast period.

Key Digital Manufacturing Companies With Capability for Biologics

Examples of leading digital manufacturing companies engaged in this industry include (which have also been captured in this report) AspenTech, Bioreactors.net, Dassault Systèmes, FUJIFILM Diosynth Biotechnologies, GE Healthcare, Körber, Merck, Sartorius and Thermo Fisher Scientific. This market report includes an easily searchable excel database of all the companies providing process analytical technology, manufacturing execution system, data analysis software and digital twin for biologic manufacturing

Recent Developments in Digital Manufacturing Market

Several recent developments have taken place in the field of digital manufacturing. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In June 2023, Kaia Health launched Angela, a HIPAA-compliant, AI-powered voice-based digital care assistant, companion, and guide with the aim to enhance physical therapy experience of the patients. 
  • In March 2023, MindMaze launched a proprietary medical device called Izar across the US and Europe with an aim to improve the hand recovery post-stroke. 

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments as defined in the below table:

Key Report Attributes Details
Base Year

2023 
Forecast Period

2023 – 2035
CAGR

18%

Type of Technology
  • Process Analytical Technology(PAT)
  • Data Analysis Software(DAS)
  • Manufacturing Execution Systems(MES)
  • Digital Twins

Deployment Options
  • Cloud-based
  • On-premises

Type(s) of Biologic(s)Manufactured
  • Antibodies
  • Cell and Gene Therapies
  • Proteins
  • Vaccines
  • Others

Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and North Africa (MENA)
  • Latin America

Key Companies Profiled
  • AspenTech
  • Bioreactors.net
  • Dassault Systèmes
  • FUJIFILM Diosynth Biotechnologies
  • GE Healthcare
  • Körber
  • Merck
  • Sartorius
  • Thermo Fisher Scientific

Customization Scope
  • 15% Free Customization Option

PowerPoint Presentation (Complimentary)
  • Available

Excel Data Packs(Complimentary)
  • Market Landscape Analysis
  • Technology Competitiveness Analysis
  • Benchmark Analysis
  • Partnerships and Collaborations
  • Market Forecast and Opportunity

The market report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this industry, across different regions. Amongst other elements, the research report includes:

  • An executive summary of the insights captured during our research, offering a high-level view on the current state of the digital biomanufacturing market and its likely evolution in the mid-long term.
  • A general introduction to digital biomanufacturing, featuring a detailed discussion on various types of technologies that support digital bioprocessing. In addition, it presents the key challenges and future perspectives associated with the employment of digital technologies in the field of biomanufacturing. 
  • A detailed assessment of the overall market landscape of digital manufacturing companies (offering digital biomanufacturing technologies - Process Analytical Technology, Data Analysis Software, Manufacturing Execution System and Digital Twin), based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of company (CDMO provider and software provider), number of platforms offered, deployment options (cloud based, on-premises, corporate datacenter and hybrid), platform capabilities (process automation, bioprocess optimization and controls, process connectivity, scalability, data integration, process monitoring and visualization, performance analysis, report generation and documentation, smart manufacturing, document control, production tracking, performance analysis and data integration), software capabilities (process intelligence, data integration, real-time process monitoring, data visualization, performance analysis and control prediction, reporting and data management), type(s) of biologic(s) manufactured, other compatible platforms (artificial intelligence / machine learning / cloud based, big data, internet of things, augmented reality and virtual reality) and type of end user(s) (industry and non-industry), integrating software (enterprise resource planning (ERP), manufacturing operation management (MOM), product lifecycle management (PLM), human resource management (HRM)), type of service(s) offered (training, implementation / upgradation and general support), area(s) of application (asset / process management, clinical trials, personalized treatment, medical training, surgical planning, health monitoring and diagnosis).
  • A detailed competitiveness analysis of digital biomanufacturing technologies (Process Analytical Technology, Data Analysis Software, Manufacturing Execution System and Digital Twin), based on supplier strength (in terms of years of experience and company size), technology portfolio (considering deployment options, number of platform capabilities, type of end user(s), software capabilities, area(s) of application, type(s) of twin(s)) and type(s) of biologic(s) manufactured.
  • Elaborate profiles of key digital manufacturing companies (companies offering more than one platform and established before 2012) engaged in the digital biomanufacturing industry, which are actively providing software based on Process Analytical Technology, Data Analysis Software, Manufacturing Execution System and Digital Twin. Each profile includes a brief overview of the company, along with information on capabilities of digital technologies offered by these firms, recent developments and an informed future outlook. 
  • A benchmark analysis highlighting the capabilities of companies (in terms of their expertise across various platforms related to the manufacturing of biologics) engaged in this industry, across key peer groups.
  • An analysis featuring information on recent partnerships inked between stakeholders engaged in this domain, based on several relevant parameters, such as year of partnership, type of partnership, type of technology, most active players (in terms of number of deals inked) and regional distribution of partnership activity, during the period 2018-2022.
  • A detailed analysis highlighting the market concentration of key industry stakeholders (companies offering more than one platform) across various regions, based on prevalent parameters, such as years of entrance, company size, type of technology, number of platforms offered and number of partnerships inked. 
  • A detailed industry lifecycle analysis that indicates various stages, including emergence, growth, maturation and eventual decline for the digital biomanufacturing industry. The primary purpose of this analysis is to develop a better understanding of the current position / phase of the industry on the lifecycle chart (based on historical trends, partnership activity and various investments made by players engaged in this domain) and predict the upcoming events that are likely to drive the growth of this domain. Further, it presents short-term and long-term impacts of various key parameters that are expected to highly impact the wider adoption of digitalization in the field of biomanufacturing.

One of the key objectives of the market report was to estimate the current opportunity and future growth potential of the digital biomanufacturing market. We have provided an informed estimate on the likely evolution of the market for the forecast period, 2023-2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of technology (Process Analytical Technology, Data Analysis Software, Manufacturing Execution System and Digital Twin), deployment options (cloud based and on-premises), type(s) of biologic(s) manufactured (antibodies, cell therapies and gene therapies, proteins, vaccines and others) and key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Joel Sirois (President and Chief Executive Officer, BioIntelligence Technologies)
  • Klaus Mauch (Managing Director and Chief Executive Officer, Yokogawa Insilico Biotechnology)
  • Ciaran O'Keeffe (Director, Business Development and Channel Sales, MasterControl) and Isura Sirisena (Quality and Manufacturing Digitization Specialist, MasterControl)
  • Yaron Halfon (Director of Sales, Trunovate)
  • Barbara Holtz (Business Consultant, Dassault Systèmes)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is the global market size of digital biomanufacturing?

Answer: The current global digital biomanufacturing market is anticipated to be worth around USD 15 billion.

Question 2: Which are the top players in the global digital biomanufacturing market?

Answer: Presently, more than 100 companies are engaged in digital biomanufacturing, worldwide. The top players engaged in this domain (which have also been captured in this report) include AspenTech, Bioreactors.net, Dassault Systèmes, FUJIFILM Diosynth Biotechnologies, GE Healthcare, Körber, Merck, Sartorius and Thermo Fisher Scientific.

Question 3: What are the factors driving the digital biomanufacturing market?

Answer: Increasing number of approved biologics, growing number of biologics-related clinical trials, rise in R&D activity and a shift in preference for cloud-based processes, over the traditional biomanufacturing operations, has bolstered the demand for digital biomanufacturing software.

Question 4: Which region has the highest market share in the global digital biomanufacturing market?

Answer: North America and Europe capture around 75% share in the current global digital biomanufacturing market, followed by Asia-Pacific.

Question 5: What are the leading market segments in digital biomanufacturing market?

Answer: Currently, in terms of type of technology, process analytical technology captures the largest share (close to 50%) in the global digital biomanufacturing market. However, digital twins are likely to witness higher annual growth rates in the upcoming years, owing to their rising popularity. Further, in terms of type of company, software providers hold the largest share in the digital biomanufacturing market as compared to CDMOs.

Question 6: Which segment, in terms of deployment options, accounts for the largest share in the global digital biomanufacturing market?

Answer: At present, the global biomanufacturing market is dominated by the players providing on-premises deployment options, while the market is anticipated to shift towards the use of cloud-based technologies in the near future.

Question 7: What are the partnership and collaboration trends in the digital biomanufacturing domain?

Answer: At present, service alliances, technology utilization agreements and acquisitions are the most prominent types of partnerships inked between various stakeholders engaged in the digital biomanufacturing domain.

Question 8: What is the growth rate (CAGR) in the global digital biomanufacturing market?

Answer: The global digital biomanufacturing market size is projected to grow at a CAGR of ~11% in the coming years

Contents

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Digital Manufacturing for Biologics
3.3. Emerging Technologies that Support Digital Manufacturing
3.3.1. Process Analytical Technology (PAT)
3.3.2. Data Analysis Software (DAS)
3.3.3. Bioprocess Digital Twin
3.3.4. Manufacturing Execution System (MES)
3.4. Challenges Associated with the Adoption of Digital Manufacturing of Biologics
3.5. Future Perspectives

4. MARKERT LANDSCAPE
4.1. Chapter Overview
4.2. List of Process Analytical Technology (PAT) Companies
4.2.1. Analysis by Year of Establishment 
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region-wise)
4.2.4. Analysis by Location of Headquarters (Country-wise)
4.2.5. Analysis by Type of Company
4.2.6. Analysis by Number of Platforms Offered
4.2.7. Analysis by Deployment Options 
4.2.8. Analysis by Platform Capabilities

4.2.9. Analysis by Type(s) of Biologic(s) Manufactured
4.2.10. Analysis by Other Compatible Platforms
4.2.11. Analysis by Type of End User(s)
4.2.12. Analysis by Year of Establishment, Location of Headquarters and Platform Capabilities
4.2.13. Analysis by Years of Experience, Location of Headquarters and Number of Platform Capabilities (Dot-Plot Representation)

4.3. List of Data Analysis Software (DAS) Companies
4.3.1. Analysis by Year of Establishment 
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters (Region-wise)
4.3.4. Analysis by Location of Headquarters (Country-wise)
4.3.5. Analysis by Type of Company
4.3.6. Analysis by Number of Software Offered
4.3.7. Analysis by Deployment Options 
4.3.8. Analysis by Software Capabilities
4.3.9. Analysis by Other Compatible Platforms
4.3.10. Analysis by Type of End User(s)
4.3.11. Analysis by Year of Establishment, Location of Headquarters and Software Capabilities
4.3.12. Analysis by Years of Experience, Location of Headquarters and Number of Software Capabilities (Dot-Plot Representation)

4.4. List of Manufacturing Execution System (MES) Companies
4.4.1. Analysis by Year of Establishment 
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters (Region-wise)
4.4.4. Analysis by Location of Headquarters (Country-wise)
4.4.5. Analysis by Type of Company
4.4.6. Analysis by Number of Platforms Offered
4.4.7. Analysis by Deployment Options 
4.4.8. Analysis by Platform Capabilities
4.4.9. Analysis by Integrating Software
4.4.10. Analysis by Type of Service(s) Offered
4.4.11. Analysis by Analysis by Years of Experience, Location of Headquarters and Number of Platform Capabilities (Dot-Plot Representation)

4.5. List of Digital Twin Companies
4.5.1. Analysis by Year of Establishment 
4.5.2. Analysis by Company Size
4.5.3. Analysis by Location of Headquarters (Region-wise)
4.5.4. Analysis by Location of Headquarters (Country-wise)
4.5.5. Analysis by Number of Platforms Offered
4.5.6. Analysis by Area(s) of Application
4.5.7. Analysis by Type of End User(s)
4.5.8. Analysis by Years of Experience, Location of Headquarters and Area(s) of Application (Dot-Plot Representation)

5. TECHNOLOGY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Technology Competitiveness Analysis: Process Analytical Technologies
5.4.1. Process Analytical Technologies Offered by Small Companies
5.4.2. Process Analytical Technologies Offered by Mid-sized Companies 
5.4.3. Process Analytical Technologies Offered by Large Companies
5.4.4. Process Analytical Technologies Offered by Very Large Companies
5.5. Technology Competitiveness Analysis: Data Analysis Software
5.6. Technology Competitiveness Analysis: Manufacturing Execution System
5.6.1. Manufacturing Execution Systems Offered by Small Companies
5.6.2. Manufacturing Execution Systems Offered by Mid-sized Companies
5.6.3. Manufacturing Execution Systems Offered by Large and Very Large Companies
5.7. Technology Competitiveness Analysis: Digital Twins

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. AspenTech
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Technology Portfolio
6.2.4. Recent Developments and Future Outlook

6.3. FUJIFILM Diosynth Biotechnologies
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Technology Portfolio
6.3.4. Recent Developments and Future Outlook

6.4. Merck
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Technology Portfolio
6.4.4. Recent Developments and Future Outlook

6.5. Thermo Fisher Scientific
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Technology Portfolio
6.5.4. Recent Developments and Future Outlook

6.6. Bioreactors.net
6.6.1. Company Overview
6.6.2. Technology Portfolio
6.6.3. Recent Developments and Future Outlook

6.7. Sartorius
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Technology Portfolio
6.7.4. Recent Developments and Future Outlook

6.8. Dassault Systèmes
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Area(s) of Application
6.8.4. Recent Developments and Future Outlook

6.9. GE Healthcare
6.9.1. Company Overview
6.9.2. Technology Portfolio
6.9.3. Recent Developments and Future Outlook

6.10. Körber
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Technology Portfolio
6.10.4. Recent Developments and Future Outlook

7. BENCHMARKING ANALYSIS
7.1. Chapter Overview
7.2. Methodology and Key Assumptions
7.3. Competitive Benchmarking by Company Size and Region
7.3.1. Competitive Benchmarking: Small Players based in North America (Peer Group I)
7.3.2. Competitive Benchmarking: Mid-sized Players based in North America (Peer Group II)
7.3.3. Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
7.3.4. Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
7.3.5. Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
7.3.6. Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
7.3.7. Competitive Benchmarking: Small, Mid-sized and Very Large Players based in Asia-Pacific (Peer Group VII)
7.4. Competitive Benchmarking: Pockets of Innovation and White Spaces

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Digital Biomanufacturing: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Technology
8.3.5. Analysis by Year of Partnership and Type of Technology
8.3.6. Most Active Players: Analysis by Number of Partnerships
8.3.7. Analysis by Geography
8.3.7.1. Intracontinental and Intercontinental Agreements
8.3.7.2. International and Local Agreements

9. MARKET CONCENTRATION ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Market Concertation Analysis: Top Digital Biomanufacturing Providers

10. INDUSTRY LIFECYCLE ANALYSIS
10.1. Chapter Overview
10.2. Industry Lifecycle Analysis

10.3. Digital Biomanufacturing: Historical Timeline of Key Events
10.4. Digital Biomanufacturing: Start-up Activity
10.5. Digital Biomanufacturing: Established Players Activity
10.6. Digital Biomanufacturing: Partnership and Collaboration Trends
10.7. Digital Biomanufacturing: Funding and Investments Trends
10.8. Current Barriers to Wider Adoption of Digitalization in Biomanufacturing
10.9. Future Outlook of Digital Biomanufacturing

10.10. Industry Lifecycle Analysis: Digital Biomanufacturing 

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Digital Manufacturing Market for Biologics, 2023-2035
11.4. Digital Manufacturing Market for Biologics: Analysis by Type of Technology
11.4.1. Process Analytical Technology Market for Biologic Manufacturing, 2023-2035
11.4.2. Data Analysis Software Market for Biologic Manufacturing, 2023-2035
11.4.3. Manufacturing Execution System Market for Biologic Manufacturing, 2023-2035
11.4.4. Digital Twin Market for Biologic Manufacturing, 2023-2035

11.5. Digital Manufacturing Market for Biologics: Analysis by Type of Deployment Options
11.5.1. Market for Cloud-based Deployment Options, 2023-2035
11.5.2. Market for On-premises Deployment Options, 2023-2035

11.6. Digital Manufacturing Market for Biologics: Analysis by Type(s) of Biologic(s) Manufactured
11.6.1. Market for Antibodies, 2023-2035
11.6.2. Market for Cell and Gene Therapies, 2023-2035
11.6.3. Market for Proteins, 2023-2035
11.6.4. Market for Vaccines, 2023-2035
11.6.5. Market for Others, 2023-2035

11.7. Digital Manufacturing Market for Biologics: Analysis by Geography
11.7.1. Market in North America, 2023-2035
11.7.2. Market in Europe, 2023-2035
11.7.3. Market in Asia-Pacific, 2023-2035
11.7.4. Market in Latin America, 2023-2035
11.7.5. Market in Middle East and North Africa, 2023-2035

12. CONCLUDING REMARKS

13. INTERVIEW TRANSCRIPTS
13.1. Chapter Overview
13.2. BioIntelligence Technologies
13.2.1. Interview Transcript: Joel Sirois, Chief Executive Officer and President

13.3. Yokogawa Insilico Biotechnology
13.3.1. Interview Transcript: Klaus Mauch, Managing Director and Chief Executive Officer

13.4. Aizon
13.4.1 Company Snapshot
13.4.2. Interview Transcript: Tudor Munteanu, Vice President of Operations and Strategic Initiatives

13.5. MasterControl
13.5.1 Company Snapshot
13.5.2. Interview Transcript: Ciaran O'Keeffe, Director, Business Development and Channel Sales, and Isura Sirisena, Quality and Manufacturing Digitization Specialist

13.6. Trunovate
13.6.1 Company Snapshot
13.6.2. Interview Transcript: Yaron Halfon, Director of Sales

13.7. Dassault Systèmes
13.7.1 Company Snapshot
13.7.2. Interview Transcript: Barbara Holtz, Business Consultant

14. APPENDIX I: TABULATED DATA

15. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Overview of Digital Biomanufacturing in Healthcare
Figure 3.2 Software Capabilities in Digital Biomanufacturing
Figure 3.3 Challenges Associated with the Adoption of Digital Biomanufacturing
Figure 4.1 Digital Biomanufacturing Companies: Distribution by Type of Technology
Figure 4.2 Process Analytical Technology Companies: Distribution by Year of Establishment
Figure 4.3 Process Analytical Technology Companies: Distribution by Company Size
Figure 4.4 Process Analytical Technology Companies: Distribution by Location of Headquarters (Region-wise)
Figure 4.5 Process Analytical Technology Companies: Distribution by Location of Headquarters (Country-wise)
Figure 4.6 Process Analytical Technology Companies: Distribution by Type of Company
Figure 4.7 Process Analytical Technology Companies: Distribution by Number of Platforms Offered
Figure 4.8 Process Analytical Technology Companies: Distribution by Deployment Options
Figure 4.9 Process Analytical Technologies: Distribution by Platform Capabilities
Figure 4.10 Process Analytical Technologies: Distribution by Type(s) of Biologic(s) Manufactured
Figure 4.11 Process Analytical Technologies: Distribution by Other Compatible Platforms
Figure 4.12 Process Analytical Technology Providers: Distribution by Type of End User(s)
Figure 4.13 Process Analytical Technologies: Distribution by Year of Establishment, Location of Headquarters and Platform Capabilities
Figure 4.14 Process Analytical Technologies offered by Small Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
Figure 4.15 Process Analytical Technologies offered by Mid-sized Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
Figure 4.16 Process Analytical Technologies offered by Large Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
Figure 4.17 Process Analytical Technologies offered by Very Large Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
Figure 4.18 Data Analysis Software Companies: Distribution by Year of Establishment
Figure 4.19 Data Analysis Software Companies: Distribution by Company Size
Figure 4.20 Data Analysis Software Companies: Distribution by Location of Headquarters (Region-wise)
Figure 4.21 Data Analysis Software Companies: Distribution by Location of Headquarters (Country-wise)
Figure 4.22 Data Analysis Software Companies: Distribution by Type of Company
Figure 4.23 Data Analysis Software Companies: Distribution by Number of Software Offered
Figure 4.24 Data Analysis Software Companies: Distribution by Deployment Options
Figure 4.25 Data Analysis Software: Distribution by Software Capabilities
Figure 4.26 Data Analysis Software: Distribution by Other Compatible Platforms
Figure 4.27 Data Analysis Providers: Distribution by Type of End User(s)
Figure 4.28 Data Analysis Software: Distribution by Year of Establishment, Location of Headquarters and Software Capabilities
Figure 4.29 Data Analysis Software Providers: Distribution by Years of Experience, Location of Headquarters and Number of Software Capabilities
Figure 4.30 Manufacturing Execution System Companies: Distribution by Year of Establishment
Figure 4.31 Manufacturing Execution System Companies: Distribution by Company Size
Figure 4.32 Manufacturing Execution System Companies: Distribution by Location of Headquarters (Region-wise)
Figure 4.33 Manufacturing Execution System Companies: Distribution by Location of Headquarters (Country-wise)
Figure 4.34 Manufacturing Execution System Companies: Distribution by Type of Company
Figure 4.35 Manufacturing Execution System Companies: Distribution by Number of Platforms Offered
Figure 4.36 Manufacturing Execution System Companies: Distribution by Deployment Options
Figure 4.37 Manufacturing Execution Systems: Distribution by Platform Capabilities
Figure 4.38 Manufacturing Execution Systems: Distribution by Integrating Software
Figure 4.39 Manufacturing Execution Systems: Distribution by Types of Service(s) Offered
Figure 4.40 Manufacturing Execution Systems Offered by Small Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
Figure 4.41 Manufacturing Execution Systems Offered by Mid-sized Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
Figure 4.42 Manufacturing Execution Systems offered by Large and Very Large Companies: Distribution by Years of Experience, Location of Headquarters and Number of Platform Capabilities
Figure 4.43 Digital Twin Companies: Distribution by Year of Establishment
Figure 4.44 Digital Twin Companies: Distribution by Company Size
Figure 4.45 Digital Twin Companies: Distribution by Location of Headquarters (Region-wise)
Figure 4.46 Digital Twin Companies: Distribution by Location of Headquarters (Country-wise)
Figure 4.47 Digital Twin Companies: Distribution by Number of Platforms Offered
Figure 4.48 Digital Twin Technologies: Distribution by Area(s) of Application
Figure 4.49 Digital Twin Companies: Distribution by Type of End User(s)
Figure 4.50 Digital Twin Companies: Distribution by Years of Experience, Location of Headquarters and Area(s) of Application
Figure 5.1 Process Analytical Technologies Offered by Small Companies
Figure 5.2 Process Analytical Technologies Offered by Mid-sized Companies
Figure 5.3 Process Analytical Technologies Offered by Large Companies
Figure 5.4 Process Analytical Technologies Offered by Very Large Companies
Figure 5.5 Technology Competitiveness Analysis: Data Analysis Software
Figure 5.6 Manufacturing Execution Systems Offered by Small Companies
Figure 5.7 Manufacturing Execution Systems Offered by Mid-sized Companies
Figure 5.8 Manufacturing Execution Systems Offered by Large and Very Large Companies
Figure 5.9 Technology Competitiveness Analysis: Digital Twins Technologies
Figure 6.1 AspenTech: Annual Revenues, FY 2020-3M 2023 (USD Million)
Figure 6.2 AspenTech: Technology Capabilities
Figure 6.3 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2018-H1 2022  (USD Million)
Figure 6.4 FUJIFILM Diosynth Biotechnologies: Technology Capabilities
Figure 6.5 Merck: Annual Revenues, FY 2018-9M 2022 (USD Billion)
Figure 6.6 Merck: Technology Capabilities
Figure 6.7 Thermo Fisher Scientific: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Figure 6.8 Thermo Fisher Scientific: Technology Capabilities
Figure 6.9 Bioreactors.net: Technology Capabilities
Figure 6.10 Sartorius: Annual Revenues, FY 2017-FY 2022 (USD Million)
Figure 6.11 Sartorius: Technology Capabilities
Figure 6.12 Dassault Systèmes: Annual Revenues, FY 2017-FY 2021 (USD Billion)
Figure 6.13 Dassault Systèmes: Area(s) of Application(s)
Figure 6.14 GE Healthcare: Technology Capabilities
Figure 6.15 Körber: Annual Revenues, FY 2019-FY 2021 (USD Million)
Figure 6.16 Körber: Technology Capabilities
Figure 7.1 Benchmark Analysis: Distribution by Company Size and Region 
Figure 7.2 Competitive Benchmarking: Small Players based in North America (Peer Group I)
Figure 7.3 Competitive Benchmarking: Mid-sized Players based in North America (Peer Group II)
Figure 7.4 Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
Figure 7.5 Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
Figure 7.6 Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
Figure 7.7 Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
Figure 7.8 Competitive Benchmarking: Small, Mid-sized, Large and Very Large Players based in Asia-Pacific (Peer Group VII)
Figure 7.9 White Spaces: Distribution of Peer Groups by Type of Technology and Type of Company
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Technology
Figure 8.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Technology
Figure 8.6 Most Active Players: Distribution by Number of Partnerships
Figure 8.7 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 8.8 Partnerships and Collaborations: International and Local Agreements
Figure 9.1 Market Concertation Analysis: Comparison of Key Offerings of Top Digital Biomanufacturing Providers
Figure 10.1 Digital Biomanufacturing: Historical Timeline of Key Events
Figure 10.2 Digital Biomanufacturing: Start-up Activity
Figure 10.3 Digital Biomanufacturing: Established Players Activity
Figure 10.4 Digital Biomanufacturing: Partnership and Collaboration Trends
Figure 10.5 Digital Biomanufacturing: Funding and Investments Trends
Figure 10.6 Current Barriers to Wider Adoption of Digitalization in Biomanufacturing
Figure 10.7 Future Outlook of Digital Biomanufacturing
Figure 10.8 Industry Lifecycle Analysis: Digital Biomanufacturing
Figure 11.1 Global Digital Manufacturing Market for Biologics, 2023-2035 (USD Million)
Figure 11.2 Digital Manufacturing Market for Biologics: Distribution by Type of Technology, 2023 and 2035
Figure 11.3 Process Analytical Technology Market for Biologic Manufacturing, 2023-2035 (USD Million)
Figure 11.4 Data Analysis Software Market for Biologic Manufacturing, 2023-2035 (USD Million)
Figure 11.5 Manufacturing Execution System Market for Biologic Manufacturing, 2023-2035 (USD Million)
Figure 11.6 Digital Twin Market for Biologic Manufacturing, 2023-2035 (USD Million)
Figure 11.7 Digital Manufacturing Market for Biologics: Distribution by Type of Deployment Options, 2023 and 2035
Figure 11.8 Digital Biomanufacturing Market for Cloud-based Deployment Options, 2023-2035 (USD Million)
Figure 11.9 Digital Biomanufacturing Market for On-premises Deployment Options, 2023-2035 (USD Million)
Figure 11.10 Digital Manufacturing Market for Biologics: Distribution by Type(s) of Biologic(s) Manufactured, 2023 and 2035
Figure 11.11 Digital Manufacturing Market for Antibodies, 2023-2035 (USD Million)
Figure 11.12 Digital Manufacturing Market for Cell and Gene Therapies, 2023-2035 (USD Million)
Figure 11.13 Digital Manufacturing Market for Proteins, 2023-2035 (USD Million)
Figure 11.14 Digital Manufacturing Market for Vaccines, 2023-2035 (USD Million)
Figure 11.15 Digital Manufacturing Market for Others, 2023-2035 (USD Million)
Figure 11.16 Digital Manufacturing Market for Biologics: Distribution by Geography, 2023 and 2035
Figure 11.17 Digital Biomanufacturing Market in North America, 2023-2035 (USD Million)
Figure 11.18 Digital Biomanufacturing Market in Europe, 2023-2035 (USD Million)
Figure 11.19 Digital Biomanufacturing Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 11.20 Digital Biomanufacturing Market in Latin America, 2023-2035 (USD Million)
Figure 11.21 Digital Biomanufacturing Market in Middle East and North Africa, 2023-2035 (USD Million)
Figure 12.1 Concluding Remarks: Market Overview of Process Analytical Technologies
Figure 12.2 Concluding Remarks: Market Overview of Data Analysis Software
Figure 12.3 Concluding Remarks: Market Overview of Manufacturing Execution Systems
Figure 12.4 Concluding Remarks: Market Overview of Digital Twins
Figure 12.5 Concluding Remarks: Partnerships and Collaborations
Figure 12.6 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 4.1 List of Process Analytical Technology Companies
Table 4.2 Process Analytical Technology Companies: Information on Platform and Deployment Options
Table 4.3 Process Analytical Technologies: Information on Platform Capabilities
Table 4.4 Process Analytical Technologies: Information on Type(s) of Biologic(s) Manufactured, Other Compatible Platforms and Type of End User(s)
Table 4.5 List of Data Analysis Software Companies
Table 4.6 Data Analysis Software Companies: Information on Deployment Options
Table 4.7 Data Analysis Software: Information on Software Capabilities
Table 4.8 Data Analysis Software: Information on Type of Biologic(s) Manufactured, Other Compatible Platforms and Type of End User(s)
Table 4.9 List of Manufacturing Execution System Companies
Table 4.10 Manufacturing Execution System Companies: Information on Deployment Options
Table 4.11 Manufacturing Execution Systems: Information on Platform Capabilities
Table 4.12 Manufacturing Execution Systems: Information on Area(s) of Application and Type of End User(s)
Table 4.13 List of Digital Twin Companies
Table 4.14 Digital Twins Technologies: Information on Area(s) of Application and Type of End User(s)
Table 5.1 Technology Competitiveness Analysis: Information on Peer Groups
Table 6.1  List of Companies Profiled
Table 6.2 AspenTech: Company Snapshot
Table 6.3 AspenTech: Recent Developments and Future Outlook
Table 6.4 FUJIFILM Diosynth Biotechnologies: Company Snapshot
Table 6.5 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 6.6 Merck: Company Snapshot
Table 6.7 Merck: Recent Developments and Future Outlook
Table 6.8 Thermo Fisher Scientific: Company Snapshot
Table 6.9 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 6.10 Bioreactors.net: Company Snapshot
Table 6.11 Sartorius: Company Snapshot
Table 6.12 Sartorius: Recent Developments and Future Outlook
Table 6.13 Dassault Systèmes: Company Snapshot
Table 6.14 GE Healthcare: Company Snapshot
Table 6.15 GE Healthcare: Recent Developments and Future Outlook
Table 6.16 Körber: Company Snapshot
Table 6.17 Körber: Recent Developments and Future Outlook
Table 7.1 Benchmark Analysis: Information on Peer Groups
Table 8.1 Digital Biomanufacturing: List of Partnerships and Collaborations, 2018-2022
Table 8.2 Digital Biomanufacturing: Information on Type of Agreement (Country-wise and Continent-wise), 2018-2022
Table 9.1 Market Concertation Analysis: Information on Years of Entrance and Key Offerings of Top Digital Biomanufacturing Providers
Table 10.1 Industry Lifecycle Analysis
Table 10.2 Industry Lifecycle Analysis: Digital Biomanufacturing
Table 13.1 BioIntelligence Technologies: Company Snapshot
Table 13.2 Yokogawa Insilico Biotechnology: Company Snapshot
Table 13.3 MasterControl: Company Snapshot
Table 13.4 Trunovate: Company Snapshot
Table 13.5 Dassault Systèmes: Company Snapshot
Table 14.1 Digital Biomanufacturing Companies: Distribution by Type of Technology
Table 14.2 Process Analytical Technology Companies: Distribution by Year of Establishment
Table 14.3 Process Analytical Technology Companies: Distribution by Company Size
Table 14.4 Process Analytical Technology Companies: Distribution by Location of Headquarters (Region-wise)
Table 14.5 Process Analytical Technology Companies: Distribution by Location of Headquarters (Country-wise)
Table 14.6 Process Analytical Technology Companies: Distribution by Type of Company
Table 14.7 Process Analytical Technology Companies: Distribution by Number of Platforms Offered
Table 14.8 Process Analytical Technology Companies: Distribution by Deployment Options
Table 14.9 Process Analytical Technologies: Distribution by Platform Capabilities
Table 14.10 Process Analytical Technologies: Distribution by Type(s) of Biologic(s) Manufactured
Table 14.11 Process Analytical Technologies: Distribution by Other Compatible Platforms
Table 14.12 Process Analytical Technology Providers: Distribution by Type of End User(s)
Table 14.13 Process Analytical Technologies: Distribution by Year of Establishment, Location of Headquarters and Platform Capabilities
Table 14.14 Data Analysis Software Companies: Distribution by Year of Establishment
Table 14.15 Data Analysis Software Companies: Distribution by Company Size
Table 14.16 Data Analysis Software Companies: Distribution by Location of Headquarters (Region-wise)
Table 14.17 Data Analysis Software Companies: Distribution by Location of Headquarters (Country-wise)
Table 14.18 Data Analysis Software Companies: Distribution by Type of Company
Table 14.19 Data Analysis Software Companies: Distribution by Number of Software Offered
Table 14.20 Data Analysis Software Companies: Distribution by Deployment Options
Table 14.21 Data Analysis Software: Distribution by Software Capabilities
Table 14.22 Data Analysis Software: Distribution by Other Compatible Platforms
Table 14.23 Data Analysis Providers: Distribution by Type of End User(s)
Table 14.24 Data Analysis Software: Distribution by Year of Establishment, Location of Headquarters and Software Capabilities
Table 14.25 Manufacturing Execution System Companies Distribution by Year of Establishment
Table 14.26 Manufacturing Execution System Companies: Distribution by Company Size
Table 14.27 Manufacturing Execution System Companies: Distribution by Location of Headquarters (Region-wise)
Table 14.28 Manufacturing Execution System Companies: Distribution by Location of Headquarters (Country-wise)
Table 14.29 Manufacturing Execution System Companies: Distribution by Type of Company
Table 14.30 Manufacturing Execution System Companies: Distribution by Number of Platforms Offered
Table 14.31 Manufacturing Execution System Companies: Distribution by Deployment Options
Table 14.32 Manufacturing Execution Systems: Distribution by Platform Capabilities
Table 14.33 Manufacturing Execution Systems: Distribution by Integrating Software
Table 14.34 Manufacturing Execution Systems: Distribution by Types of Service(s) Offered
Table 14.35 Digital Twin Companies: Distribution by Year of Establishment
Table 14.36 Digital Twin Companies: Distribution by Company Size
Table 14.37 Digital Twin Companies: Distribution by Location of Headquarters (Region-wise)
Table 14.38 Digital Twin Companies: Distribution by Location of Headquarters (Country- wise)
Table 14.39 Digital Twin Companies: Distribution by Number of Platforms Offered
Table 14.40 Digital Twins Technologies: Distribution by Area(s) of Application
Table 14.41 Digital Twin Companies: Distribution by Type of End User(s)
Table 14.42 AspenTech: Annual Revenues, FY 2020-3M 2023 (USD Million)
Table 14.43 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2018-H1 2022 (USD Million)
Table 14.44 Merck: Annual Revenues, FY 2018-9M 2022 (USD Billion)
Table 14.45 Thermo Fisher Scientific: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Table 14.46 Sartorius: Annual Revenues, FY 2017-FY 2022 (USD Million)
Table 14.47 Dassault Systèmes: Annual Revenues, FY 2017-FY 2021 (USD Billion)
Table 14.48 Körber: Annual Revenues, FY 2019-FY 2021 (USD Million)
Table 14.49 Benchmark Analysis: Distribution by Company Size and Region
Table 14.50 Partnerships and Collaborations: Distribution by Year of Partnership
Table 14.51 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.52 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 14.53 Partnerships and Collaborations: Distribution by Type of Technology
Table 14.54 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Technology
Table 14.55 Most Active Players: Distribution by Number of Partnerships
Table 14.56 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 14.57 Partnerships and Collaborations: International and Local Agreements
Table 14.58 Digital Biomanufacturing: Start-up Activity
Table 14.59 Global Digital Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.60 Digital Manufacturing Market for Biologics: Distribution by Type of Technology, 2023 and 2035
Table 14.61 Process Analytical Technology Market for Biologic Manufacturing, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.62 Data Analysis Software Market for Biologic Manufacturing, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.63 Manufacturing Execution System Market for Biologic Manufacturing, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.64 Digital Twin Market for Biologic Manufacturing, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.65 Digital Manufacturing Market for Biologic: Distribution by Type of Deployment Options, 2023 and 2035
Table 14.66 Digital Biomanufacturing Market for Cloud-based Deployment Options, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.67 Digital Biomanufacturing Market for On-premises Deployment Options, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.68 Digital Manufacturing Market for Biologic: Distribution by Type(s) of Biologic(s) Manufactured, 2023 and 2035
Table 14.69 Digital Manufacturing Market for Antibodies, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.70 Digital Manufacturing Market for Cell and Gene Therapies, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.71 Digital Manufacturing Market for Proteins, Conservative, Base and OptimisticScenario, 2023-2035 (USD Million)
Table 14.72 Digital Manufacturing Market for Vaccines, Conservative, Base and OptimisticScenario, 2023-2035 (USD Million)
Table 14.73 Digital Manufacturing Market for Others, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.74 Digital Manufacturing Market for Biologics: Distribution by Geography, 2023 and 2035
Table 14.75 Digital Manufacturing Market in North America, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.76 Digital Manufacturing Market in Europe, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.77 Digital Manufacturing Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.78 Digital Manufacturing Market in Latin America, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)
Table 14.79 Digital Manufacturing Market in Middle East and North Africa, Conservative, Base and Optimistic Scenario, 2023-2035 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 908 Devices
  2. Sciex
  3. ABB
  4. Advanced Instruments
  5. Aegis Software
  6. Aggity
  7. Agilent Technologies
  8. Agilitech
  9. Aizon
  10. Ajinomoto
  11. Akron Biotech
  12. Alit Life Science
  13. Amazon Web Services
  14. Amgen
  15. Andrew Alliance
  16. APC
  17. Applied Materials
  18. Apprentice
  19. Arranta Bio
  20. Asimov
  21. AspenTech
  22. Atachi Systems
  23. Atos
  24. Automated Engineering Services (AES)
  25. Avantor
  26. AVEVA
  27. AX for Pharma
  28. BASE
  29. Beckman Coulter
  30. Benchling
  31. Bigfinite
  32. Bioengineering
  33. Biofactory Competence Centre
  34. Biofors Global
  35. BioIntelligence Technologies
  36. Bionet
  37. BioNTech
  38. BioPharm
  39. Bioprocess Technology
  40. Bioreactors.net
  41. BiOZEEN
  42. Birlasoft
  43. Bluecrux
  44. BlueSens
  45. Boan Biotech
  46. Bota Biosciences
  47. Caffeinated Capital
  48. CanCell Therapeutics
  49. Catapult Ventures
  50. CellPort
  51. Centre for Process Innovation
  52. COPA DATA
  53. CPI
  54. Creonis
  55. Cultivian Sandbox Ventures
  56. Culture Biosciences
  57. Cytiva
  58. CytomX Therapeutics
  59. Danyel Biotech
  60. Daspool
  61. Dassault Systèmes
  62. DataHow
  63. Diamyd Medical
  64. DRS Daylight Solutions
  65. Dutch State Mines (DSM)
  66. Emerson
  67. Encoded Therapeutics
  68. Enlight Technology
  69. Eppendorf
  70. Exyte
  71. FASTEC 
  72. Ferring Pharmaceuticals
  73. Flownamics
  74. Fluxa
  75. FUJIFILM Diosynth Biotechnologies
  76. Ganymede Bio
  77. GE Healthcare
  78. Gemma Frisius
  79. Genedata
  80. GenSensor
  81. GoSilico 
  82. Gramener
  83. Gritstone Oncology
  84. Hamilton
  85. Hexagon
  86. Honeywell
  87. Icosagen
  88. IDBS
  89. ILS Automation
  90. Infors
  91. Infoteam Automation
  92. inmation Software
  93. Insilico Biotechnology
  94. Integra CMS
  95. Integrix Solutions
  96. Inventrax 
  97. Körber
  98. Kuhner
  99. KYDEA
  100. KYNOTA
  101. Laurus Infosystems
  102. Leanios
  103. Light Chain Bioscience
  104. LRM
  105. LZ Lifescience
  106. MastersControl
  107. Merck
  108. MERSEN
  109. Metronik
  110. Microbial Bioprocess Lab (MiBioLab)
  111. Microsaic Systems
  112. Microsoft
  113. MiNK Therapeutics
  114. MPDV
  115. MyCellHub
  116. Naobios
  117. National Physical Laboratory
  118. North Carolina State University
  119. Northpond Ventures
  120. Noshaq
  121. Novasign
  122. Octapharma
  123. Optimal Industrial Automation
  124. Orion Pharma
  125. OSPIN
  126. Overwatch Research
  127. Ovizio
  128. OVO Biomanufacturing
  129. Pall Corporation
  130. PendoTECH
  131. Perceptive Engineering
  132. PerkinElmer
  133. Pierre Guérin
  134. POMS
  135. PTC
  136. Purdue University
  137. QM Consulting
  138. Qubicon
  139. Repligen
  140. RESOLUTION Spectra Systems
  141. Rockwell Automation
  142. RoosterBio
  143. Sapio Sciences
  144. Sartorius
  145. Scientific Bioprocessing
  146. SCIEX
  147. Scispot.io
  148. Section 32
  149. Securecell
  150. Sensum
  151. Sequence
  152. Sequoia Capital China
  153. Shimadzu
  154. Siemens
  155. Skyland Analytics
  156. Smart Pharma Soft Solutions
  157. Solaris Biotechnology
  158. StreamNative
  159. Synthace
  160. TetraScience
  161. Teva Pharmaceuticals
  162. The CoFoundry
  163. The Faktory Fund
  164. Thermo Fisher Scientific
  165. Transcenta
  166. Trunovate
  167. Tulip
  168. ValitaCell
  169. Vimachem
  170. Vineti
  171. WisdomEngine
  172. Wyoming
  173. Xenomics
  174. Yokogawa Insilico Biotechnology
  175. Zenith Technologies
  176. ZETA

Source 1: https://bioprocessintl.com/manufacturing/information-technology/the-era-of-digital-biomanufacturing/
Source 2: https://www.nature.com/articles/s41587-022-01630-6

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.